At the beginning of the 2022-2023 academic year, Jamie Dwyer, MD was appointed as the new School of Medicine Associate Dean for Clinical Research. Dr. Dwyer assumed this position on July 1st of this year, replacing Michael Dean, MD, MBA who had served in the position for the last several years.
Regarding the appointment, Rachel Hess, MD, MS, AVP for Research, and Chris Hill, DPhil, SOM Dean for Research joined in writing, “Jamie Dwyer brings deep expertise in the design, conduct, and analysis of large-scale randomized clinical trials. His experience at Vanderbilt University demonstrates a track record of excellence at in building and leading teams in the university context. He is a spectacular choice to help University of Utah Health achieve its considerable potential in clinical research.”
Dr. Dwyer is a professor of medicine in the division of nephrology and hypertension, and director of both the Utah Data Coordinating Center and the Clinical Research Support Office in the Clinical and Translational Science Institute at the U.
He is currently Chair of the Board, President, and Principal Investigator of the nonprofit organization the Collaborative Study Group (CSG), an international academic research organization dedicated to the exceptionally rigorous design, conduct, analysis, and reporting of large, international clinical trials. He has served on multiple executive and steering committees for large trials, particularly in CKD progression and cardiovascular outcomes.
Dr. Dwyer is a practicing clinical nephrologist who sees patients across the full spectrum of kidney disease. He is an accomplished and highly lauded educator, receiving numerous teaching awards, culminating in his election to Vanderbilt’s Academy for Excellence in Education in 2013/
Dr. Dwyer holds an ScB degree in Mathematics and Latin from Brown University in 1996, and an MD with Distinction from Brown University Medical School in 2000. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at VUMC. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of VUMC in 2008.
About University of Utah Health:
“University of Utah Health is the only academic medical center in the state of Utah and provides patient care for the people of Utah, Idaho, Wyoming, Montana, western Colorado, and much of Nevada. It also serves as the training ground for scientists and the majority of the state’s physicians, nurses, pharmacists, dentists, therapists, and other health care professionals.
University of Utah Health’s School of Medicine jumped a healthy 28 spots in the US News and World Report medical school rankings in primary care. With one of the nation’s highest faculty-to-student ratios and a seamless integration with our 23 departments, students, residents, and fellows receive deep exposure to pioneering efforts in health care value and quality. Our School of Medicine students find themselves in a culture of care unlike any other school.”
About Jamie Dwyer, MD:
“My clinical expertise centers around kidney disease (in general) but specifically diabetic kidney disease and other glomerular lesions, including glomerulonephritis. I have also developed expertise in the evaluation, management, and prevention of kidney stones (nephrolithiasis). My clinical research has focused on these areas as well, particularly on the design, conduct, and analysis of large-scale randomized clinical trials (RCT) in nephrology and hypertension, particularly in delaying the progression of chronic kidney disease (CKD). I am the Co-Director of the Vanderbilt Nephrology Clinical Trials Center, a founding part of the Vanderbilt Center for the Study of Kidney Disease. Additionally, I am an Officer of the Collaborative Study Group (CSG), a international, non-profit organization dedicated to the exceptionally rigorous design and analysis and safe conduct of pilot and multinational, large-scale, pivotal RCTs in relevant therapeutic areas, including CKD, diabetic nephropathy, lupus, lupus nephritis, and end-stage renal disease. My expertise centers around protocol design, medical monitoring, trial conduct, and safety.
My clinical research has focused on the design, conduct, and analysis of large-scale randomized clinical trials (RCT) in nephrology and hypertension, particularly in delaying the progression of chronic kidney disease (CKD). I am the Co-Director of the Vanderbilt Nephrology Clinical Trials Center, a founding part of the Vanderbilt Center for the Study of Kidney Disease. Additionally, I am an Officer of the Collaborative Study Group (CSG), a international, non-profit organization dedicated to the exceptionally rigorous design and analysis and safe conduct of pilot and multinational, large-scale, pivotal RCTs in relevant therapeutic areas, including CKD, diabetic nephropathy, lupus, lupus nephritis, and end-stage renal disease. My expertise centers around protocol design, medical monitoring, trial conduct, and safety. I have participated on numerous Protocol Design, M&M, and DSMB committees. I have served as the Medical Monitor for multiple compounds and trials, detailed below. To support my expertise in safe conduct of trials, I currently serve as the Vice-Chair of my University’s Health Science’s Institutional Review Board. I have analyzed renal safety signals in non-renal clinical trials presented to the FDA. Additionally, I am interested in investigating alternative, proximal outcomes in large RCTs in nephrology which will increase event rates, reduce follow-up time, and reduce sample sizes, in order to speed intervention development to delay the progression of CKD. Finally, as part of this interest in endpoint analysis, I am interested in the measurement of renal function and its implications for the design and choice of endpoints in large RCTs.”
Sources:
News: https://uofuhealth.utah.edu/news/2022/09/jamie-dwyer-md-appointed-som-associate-dean-clinical-research
School: https://uofuhealth.utah.edu/about
Jamie Dwyer, MD: https://labnodes.vanderbilt.edu/member/profile/id/10633